Guidelines for investigating causality of sequence variants in human disease

D G MacArthur, T A Manolio, D P Dimmock, H L Rehm, J Shendure, G R Abecasis, D R Adams, R B Altman, S E Antonarakis, E A Ashley, J C Barrett, L G Biesecker, D F Conrad, G M Cooper, N J Cox, M J Daly, M B Gerstein, D B Goldstein, J N Hirschhorn, S M Leal, L A Pennacchio, J A Stamatoyannopoulos, S R Sunyaev, D Valle, B F Voight, W Winckler, C Gunter, D G MacArthur, T A Manolio, D P Dimmock, H L Rehm, J Shendure, G R Abecasis, D R Adams, R B Altman, S E Antonarakis, E A Ashley, J C Barrett, L G Biesecker, D F Conrad, G M Cooper, N J Cox, M J Daly, M B Gerstein, D B Goldstein, J N Hirschhorn, S M Leal, L A Pennacchio, J A Stamatoyannopoulos, S R Sunyaev, D Valle, B F Voight, W Winckler, C Gunter

Abstract

The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing disease-causing sequence variants from the many potentially functional variants present in any human genome are urgently needed. Without rigorous standards we risk an acceleration of false-positive reports of causality, which would impede the translation of genomic research findings into the clinical diagnostic setting and hinder biological understanding of disease. Here we discuss the key challenges of assessing sequence variants in human disease, integrating both gene-level and variant-level support for causality. We propose guidelines for summarizing confidence in variant pathogenicity and highlight several areas that require further resource development.

References

    1. Bell CJ, et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci. Transl. Med. 2011;3:65ra4.
    1. Xue Y, et al. Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am. J. Hum. Genet. 2012;91:1022–1032.
    1. Norton N, et al. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet. 2012;5:167–174.
    1. Weng L, et al. Lack of MEF2A mutations in coronary artery disease. J. Clin. Invest. 2005;115:1016–1020.
    1. Hunt KA, et al. Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nature Genet. 2012;44:3–5.
    1. Allen AS, et al. De novo mutations in epileptic encephalopathies. Nature. 2013;501:217–221.
    1. Manolio TA, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–753.
    1. Bamshad MJ, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nature Rev. Genet. 2011;12:745–755.
    1. Kiezun A, et al. Exome sequencing and the genetic basis of complex traits. Nature Genet. 2012;44:623–630.
    1. Pasaniuc B, et al. Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nature Genet. 2012;44:631–635.
    1. Li B, Wang G, Leal SM. SimRare: a program to generate and analyze sequence-based data for association studies of quantitative and qualitative traits. Bioinformatics. 2012;28:2703–2704.
    1. Johnston JJ, et al. The phenotype of a germline mutation in PIGA: the gene somatically mutated in paroxysmal nocturnal hemoglobinuria. Am. J. Hum. Genet. 2012;90:295–300.
    1. Zuk O, et al. Searching for missing heritability: Designing rare variant association studies. Proc. Natl Acad. Sci USA. 2014;111:E445–E464.
    1. Chanock SJ, et al. Replicating genotype–phenotype associations. Nature. 2007;447:655–660.
    1. O’Connor TD, et al. Fine-scale patterns of population stratification confound rare variant association tests. PLoS ONE. 2013;8:e65834.
    1. Mathieson I, McVean G. Differential confounding of rare and common variants in spatially structured populations. Nature Genet. 2012;44:243–246.
    1. Goldstein DB, et al. Sequencing studies in human genetics: design and interpretation. Nature Rev. Genet. 2013;14:460–470.
    1. de Ligt J, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 2012;367:1921–1929.
    1. Rauch A, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet. 2012;380:1674–1682.
    1. Sanders SJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485:237–241.
    1. O'Roak BJ, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485:246–250.
    1. Neale BM, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485:242–245.
    1. Iossifov I, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74:285–299.
    1. O'Roak BJ, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012:1619–1622.
    1. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nature Genet. 1995;11:241–247.
    1. Harrow J, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22:1760–1774.
    1. Derrien T, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22:1775–1789.
    1. Ng SB, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nature Genet. 2010;42:790–793.
    1. Lemaire M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nature Genet. 2013;45:531–536.
    1. Albers CA, et al. Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon–junction complex subunit RBM8A causes TAR syndrome. Nature Genet. 2012;44:435–439.
    1. Zaidi S, et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature. 2013;498:220–223.
    1. Lage K, et al. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc. Natl Acad. Sci. USA. 2008;105:20870–20875.
    1. Franke L, et al. Reconstruction of a functional human gene network, with an application for prioritizing positional candidate genes. Am. J. Hum. Genet. 2006;78:1011–1025.
    1. Boulding H, Webber C. Large-scale objective association of mouse phenotypes with human symptoms through structural variation identified in patients with developmental disorders. Hum. Mutat. 2012;33:874–883.
    1. Webber C, et al. Forging links between human mental retardation-associated CNVs and mouse gene knockout models. PLoS Genet. 2009;5:e1000531.
    1. Reed DR, Lawler MP, Tordoff MG. Reduced body weight is a common effect of gene knockout in mice. BMC Genet. 2008;9:4.
    1. Giallourakis C, Henson C, Reich M, Xie X, Mootha VK. Disease gene discovery through integrative genomics. Annu. Rev. Genomics Hum. Genet. 2005;6:381–406.
    1. Tennessen JA, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337:64–69.
    1. Veltman JA, Brunner H. G. De novo mutations in human genetic disease. Nature Rev. Genet. 2012;13:565–575.
    1. Bustamante CD, et al. Natural selection on protein-coding genes in the human genome. Nature. 2005;437:1153–1157.
    1. MacArthur DG, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science. 2012;335:823–828.
    1. Cooper GM, Shendure J. Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nature Rev. Genet. 2011;12:628–640.
    1. Adzhubei IA, et al. A method and server for predicting damaging missense mutations. Nature Methods. 2010;7:248–249.
    1. Cooper GM, et al. Single-nucleotide evolutionary constraint scores highlight disease-causing mutations. Nature Methods. 2010;7:250–251.
    1. Kondrashov AS, Sunyaev S, Kondrashov FA. Dobzhansky-Muller incompatibilities in protein evolution. Proc. Natl Acad. Sci. USA. 2002;99:14878–14883.
    1. The ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
    1. Patwardhan RP, et al. Massively parallel functional dissection of mammalian enhancers in vivo. Nature Biotechnol. 2012;30:265–270.
    1. Cooper GM, et al. A copy number variation morbidity map of developmental delay. Nature Genet. 2011;43:838–846.
    1. Bick AG, et al. Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. Am. J. Hum. Genet. 2012;91:513–519.
    1. Flannick J, et al. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nature Genet. 2013:1380–1385.
    1. 1000 Genomes Project Consortium A map of human genome variation from population-scale sequencing. Nature. 2010;467:1061–1073. corrigendum 473, 544 (2011).
    1. Editorial Share alike. Nature. 2012;490:143–144.
    1. Fokkema IF, et al. LOVD v.2.0: the next generation in gene variant databases. Hum. Mutat. 2011;32:557–563.
    1. Firth HV, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am. J. Hum. Genet. 2009;84:524–533.
    1. Walport M, Brest P. Sharing research data to improve public health. Lancet. 2011;377:537–539.
    1. Altshuler DA, et al. Creating a global alliance to enable responsible sharing of genomic and clinical data. 2013 .
    1. Richards CS, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet. Med. 2008;10:294–300.
    1. Gargis AS, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nature Biotechnol. 2012;30:1033–1036.
    1. Rehm HL, et al. ACMG Clinical Laboratory Standards for Next Generation Sequencing. Genet. Med. 2013 (in the press)

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever